Abstract
Background Among systemic abnormalities caused by the novel coronavirus, little is known about the critical attack on the central nervous system (CNS). Few studies have shown cerebrovascular pathologies that indicate CNS involvement in acute patients. However, replication studies are necessary to verify if these effects persist in COVID-19 survivors more conclusively. Furthermore, recent studies indicate fatigue is highly prevalent among ‘long-COVID’ patients. How morphometry in each group relate to work-related fatigue need to be investigated.
Method COVID survivors were MRI scanned two weeks after hospital discharge. We hypothesized, these survivors will demonstrate altered gray matter volume (GMV) and experience higher fatigue levels when compared to healthy controls, leading to stronger correlation of GMV with fatigue. Voxel-based morphometry was performed on T1-weighted MRI images between 46 survivors and 30 controls. Unpaired two-sample t-test and multiple linear regression were performed to observe group differences and correlation of fatigue with GMV.
Results The COVID group experienced significantly higher fatigue levels and GMV of this group was significantly higher within the Limbic System and Basal Ganglia when compared to healthy controls. Moreover, while a significant positive correlation was observed across the whole group between GMV and self-reported fatigue, COVID subjects showed stronger effects within the Posterior Cingulate, Precuneus and Superior Parietal Lobule.
Conclusion Brain regions with GMV alterations in our analysis align with both single case acute patient reports and current group level neuroimaging findings. We also newly report a stronger positive correlation of GMV with fatigue among COVID survivors within brain regions associated with fatigue, indicating a link between structural abnormality and brain function in this cohort.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by an NIH grant (R01AT009829).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committee/IRB of Indian Institute of Technology (IIT), Delhi, India, gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The revised version of the manuscript has undergone the following changes: 1. Abstract has been rewritten in a structured format. 2. Introduction has been made more concise. 3. Additional clinical information pertaining to COVID survivors has been added under Participants in Materials and Methods. 4. Non-stationary cluster-based thresholding has been adopted at a more conservative height threshold of p < 0.001 for the t-test 5. Fatigue scores from Healthy group has also been added and group level difference with COVID group has been reported. 6. The voxelwise correlation analysis has been updated with scores from both Healthy and COVID groups and new results have been reported. 7. Discussion on the cluster reported in the previous manuscript has been added in the Discussion section and relevant results added in the Supplementary Material document as Figure S2 8. Figures 1 and 2 have been combined to make Figure 1 in the revised manuscript. 9. Figure 3 in the previous manuscript has been moved to the Supplementary Material document as Figure S1
Data Availability
All data produced in the present study are available upon reasonable request to the authors
